Fig. 2: Bisthianostat induces significant anti-MM activity in vivo. | Acta Pharmacologica Sinica

Fig. 2: Bisthianostat induces significant anti-MM activity in vivo.

From: Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

Fig. 2

a–c RPMI-8226 plasmacytoma model was treated with vehicle (n = 12), BIS (50, 75, 100 mg·kg-1·d-1, BID, n = 6), SAHA (75 mg·kg-1·d-1, BID, n = 6), and bortezomib (1 mg·kg-1·d-1, i.v., D1/4, n = 6) for 18 days. Tumor growth volume (a) and tumor weight (b) were significantly inhibited in the BIS treated group compared with controls, in dose-dependent manner, and BIS treatment did not significantly affect the body weight of the animals (c). d–f MM.1S plasmacytoma model was treated with vehicle (n = 12), BIS (50, 75, 100 mg·kg-1·d-1, BID, n = 6), SAHA (75 mg·kg-1·d-1, BID, n = 6), and bortezomib (1 mg·kg-1·d-1, i.v., D1/4, n = 6) for 18 days. Tumor growth volume (d) and tumor weight (e) were significantly inhibited in the BIS treated group compared with controls, in dose-dependent manner. BIS treatment did not significantly affect the body weight of the animals (f).

Back to article page